Clinical Trial Detail

NCT ID NCT03635983
Title A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Nivolumab

Nivolumab + NKTR-214

Age Groups: senior adult child

No variant requirements are available.